- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
First Helium
Black Swan Graphene
Purpose Bitcoin ETF
Soma Gold Corp.
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Market Forecast: Top Trends That Will Affect Cannabis in 2024
After a tough year, what's the 2024 forecast for the cannabis market? Here's a look at the trends experts see coming.
The cannabis industry is maturing, but after a tough 2023 challenges remain for companies and investors.
In Canada, the sector continues to go through a much-needed rightsizing, while in the US all eyes are on reform. Looking further afield, international markets are gradually changing legislation surrounding the drug.
To find out what's coming for the cannabis space in 2024, the Investing News Network (INN) reached out to experts to learn about the key trends and challenges they expect to see. Here's what they had to say.
Rightsizing to continue in Canadian market
Five years after legalization, Nawan Butt, portfolio manager at Purpose Investments, sees maturity for the Canadian cannabis market. “In Canada, after years of equilibrium discovery, we're starting to get to a point where the market is approaching rightsizing," he told INN. "Demand was picking up slowly with the excessive supply that was within the market, but now we're starting to see that Canada is on its way to achieving its terminal demand goals, where penetration rates are increasing, distribution is becoming easier and access for Canadians is becoming easier.”
Butt said he is observing this trend on the supply side of the sector. “The infrastructure that was created for a massive oversupply is now being rightsized. The industry has seen that producers were way too far ahead in terms of demand anticipation (when the infrastructure was created), and now they’re starting to get to a size where equilibrium between supply and demand can be reached, which causes a healthier industry," he noted.
Butt believes this trend will continue into 2024. And while bankruptcies and M&A may persist as well, he doesn't believe there will be as much as there has been over the last two years, at least not in Canada. “A lot of the weaker players have been weeded out, for lack of a better word. We're already in a place where it's a tight group that has market share and control. And from here on, they seem to be fairly well capitalized for the next phase of growth as well. So even though there will continue to be a further rightsizing of the market, the majority of that is behind us," he said.
Stateside, the landscape looks much different. “In the US, it's really a question of how quickly regulation can change, because that is the lifeline that many smaller producers are hoping for. If there is no material progress, then you could see more bankruptcies take place. There is the opportunity to have small M&As, but a lot of the companies that are willing to sell here have pretty unattractive capital structures," said Butt.
Access to capital a big US market concern
When it comes to catalysts within the cannabis market, Rami El-Cheikh, corporate strategy partner at EY-Parthenon, pointed to limited access to capital markets as one of the biggest concerns facing the US market.
“A lot of the cannabis companies (are) not profitable, (and are) relying on the capital markets to raise money and continue to sustain their operations. Because of the underperformance in the cannabis industry, (raising capital) could be even more challenging for these cannabis companies," he explained to INN.
“I think there's going to be more acceleration of bankruptcies and restructurings in 2024. I think the balance sheets are very stretched. So that's going to be very problematic, and (even though) a lot of the cannabis companies have been very active with their cost-reduction programs, I don't know to what extent they can further reduce costs and further streamline their operations. They've been at it for about a year or two years now. So without improved capital markets (or) competitors exiting the market, it's going to continue to be a challenging, challenging industry.”
Butt echoed El-Cheikh’s statement. “(Limited financial access) is also concerning for producers because … it really becomes a world of haves and have-nots; it takes away a level playing field and really gives the advantage to those that have lots of money in their coffers, and turns the structure more into an oligopolistic structure rather than a (truly) competitive market, which is not good for consumers at the end of the day," he said.
2023 saw a few US operators apply to list on Canadian exchanges, which would increase their visibility and unlock access to capital from foreign investors. If their moves prove successful, more US operators may follow suit in 2024.
US election could politicize cannabis sector
With Minnesota, Ohio and Delaware all passing laws to legalize the adult use of cannabis in 2023, and the US Department of Health and Human Service recommending that the US Drug Enforcement Administration reschedule the drug, it’s clear that public opinion on cannabis legalization is changing quickly. As the US enters the 2024 election cycle, the industry could take center stage as politicians look for ways to build platforms that resonate with voters.
However, Butt does not believe politicizing reform will be good for the US cannabis market. “(Politicization) could stall the progress that has been made so far, and really leave investors (and operators) out to dry. It could put them in a little bit of limbo as they figure out how to navigate the waters of limited financial access and growing underlying markets.”
The advancement of the SAFER Banking Act seemed like a promising sign when it was voted on back in September. “Certainly the scenario now is very different than it was three, four or five years ago,” noted Butt.
“(However)," he added, "We are sitting in a scenario where the House is now controlled by Republicans who might not want to give Democrats a win. So political posturing is going to be front and center for the future of the SAFER Act, at least within the next 12 months going into the election cycle.”
Global cannabis market growth to continue
Cannabis legalization is spreading. Countries in South America, Asia and Europe are considering some type of cannabis reform, possibly in 2024. As regulatory changes create investment opportunities around the world, it’s likely the demand for cannabis in these untapped markets will grow. In fact, according to Grand View Research, the global cannabis market is projected to grow at a compound annual growth rate of 25.5 percent between 2023 and 2030.
“Germany has been working through the challenges of how to stage the proliferation of cannabis … and the holes that were left with the Canadian blueprint are being stitched by the German regulation that's developing,” said Butt.
Major cannabis companies Tilray Brands, Curaleaf Holdings (OTCQX:CURLF,CSE:CURA), Cronos Group (NASDAQ:CRON,TSX:CRON), Organigram Holdings (NASDAQ:OGI,TSX:OGI) and Aurora Cannabis (NASDAQ:ACB,TSX:ACB) have all expanded into the German market in 2022 and 2023.
The bottom line
The cannabis market has been tough for companies and investors over the last few years, but there is some optimism that 2024 will bring much-needed action that will allow the industry to realize its full potential. And as regulation changes around the world open the door to new opportunities, the global market could be poised for significant growth.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Meagen moved to Vancouver in 2019 after splitting her time between Australia and Southeast Asia for three years. She worked simultaneously as a freelancer and childcare provider before landing her role as an Investment Market Content Specialist at the Investing News Network.
Meagen has studied marketing, developmental and cognitive psychology and anthropology, and honed her craft of writing at Langara College. She is currently pursuing a degree in psychology and linguistics. Meagen loves writing about the life science, cannabis, tech and psychedelics markets. In her free time, she enjoys gardening, cooking, traveling, doing anything outdoors and reading.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Meagen moved to Vancouver in 2019 after splitting her time between Australia and Southeast Asia for three years. She worked simultaneously as a freelancer and childcare provider before landing her role as an Investment Market Content Specialist at the Investing News Network.
Meagen has studied marketing, developmental and cognitive psychology and anthropology, and honed her craft of writing at Langara College. She is currently pursuing a degree in psychology and linguistics. Meagen loves writing about the life science, cannabis, tech and psychedelics markets. In her free time, she enjoys gardening, cooking, traveling, doing anything outdoors and reading.
Learn about our editorial policies.